HSG4112

HSG4112
法律規範狀態
法律規範	Investigational;
識別資訊
	IUPAC命名法 2-(8,8-Dimethyl-3,4,9,10-tetrahydro-2H-pyrano[2,3-h]chromen-3-yl)-5-ethoxyphenol; ;
CAS號	1800188-47-9
PubChem CID	118204185;
UNII	7AWD9J49UP = 7AWD9J49UP;
化學資訊
化學式	C22H26O4
摩爾質量	354.45 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES OC1=CC(OCC)=CC=C1C2COC=3C(=CC=C4OC(C)(C)CCC43)C2;

Vutiglabridin（中文譯名未知），開發代號HSG4112，是一種外消旋的有機化合物，化學式為C₂₂H₂₆O₄，為實驗性抗肥胖藥物，是光甘草定（英語：glabridin）的結構類似物。^[1]^[2]^[3]

它可以5-羥基-2,2-二甲基-2H-1-苯並呋喃-6-甲醛為原料經多步反應製得。^[4]

參考文獻

^ Hyeon, Jooseung; Lee, Jihan; Kim, Eunju; Lee, Hyeong Min; Kim, Kwang Pyo; Shin, Jaejin; Park, Hyung Soon; Lee, Yun-Il; Nam, Chang-Hoon. Vutiglabridin exerts anti-ageing effects in aged mice through alleviating age-related metabolic dysfunctions. Experimental Gerontology. October 2023, 181: 112269. doi:10.1016/j.exger.2023.112269 .
^ Na, Joo Young; Yoon, Deok Yong; Yoo, Hyounggyoon; Lee, SeungHwan; Yu, Kyung‐Sang; Jang, In‐Jin; Yoo, Sang‐Ku; Kim, Youngah; Oh, Jaeseong. Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study. Clinical and Translational Science. November 2022, 15 (11): 2744–2757. ISSN 1752-8054. PMC 9652434 . doi:10.1111/cts.13401 （英語）.
^ Choi, Leo Sungwong; Jo, In Geun; Kang, Ku Suk; Im, Jeong Ho; Kim, Jiyoung; Kim, Jinyoung; Chung, Jin Wook; Yoo, Sang-Ku. Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity. International Journal of Obesity. January 2021, 45 (1): 130–142 [2023-12-14]. ISSN 1476-5497. doi:10.1038/s41366-020-00686-1 . （原始內容存檔於2023-12-20）（英語）.
^ Yoo, Sang Ku; Chung, Jin Wook; Jo, In Geun; Im, Jeong Ho; Kang, Ku Suk; Kim, Jin Young. Pyranochromenyl-phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease. 2015. WO2015099392（韓文） / 2014. CN105849111A（中文） / 2016. US2016272650A1（英文）.

[1] Hyeon, Jooseung; Lee, Jihan; Kim, Eunju; Lee, Hyeong Min; Kim, Kwang Pyo; Shin, Jaejin; Park, Hyung Soon; Lee, Yun-Il; Nam, Chang-Hoon. Vutiglabridin exerts anti-ageing effects in aged mice through alleviating age-related metabolic dysfunctions. Experimental Gerontology. October 2023, 181: 112269. doi:10.1016/j.exger.2023.112269 .

[2] Na, Joo Young; Yoon, Deok Yong; Yoo, Hyounggyoon; Lee, SeungHwan; Yu, Kyung‐Sang; Jang, In‐Jin; Yoo, Sang‐Ku; Kim, Youngah; Oh, Jaeseong. Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study. Clinical and Translational Science. November 2022, 15 (11): 2744–2757. ISSN 1752-8054. PMC 9652434 . doi:10.1111/cts.13401 （英語）.

[3] Choi, Leo Sungwong; Jo, In Geun; Kang, Ku Suk; Im, Jeong Ho; Kim, Jiyoung; Kim, Jinyoung; Chung, Jin Wook; Yoo, Sang-Ku. Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity. International Journal of Obesity. January 2021, 45 (1): 130–142 [2023-12-14]. ISSN 1476-5497. doi:10.1038/s41366-020-00686-1 . （原始內容存檔於2023-12-20）（英語）.

[4] Yoo, Sang Ku; Chung, Jin Wook; Jo, In Geun; Im, Jeong Ho; Kang, Ku Suk; Kim, Jin Young. Pyranochromenyl-phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease. 2015. WO2015099392（韓文） / 2014. CN105849111A（中文） / 2016. US2016272650A1（英文）.

[1]

[2]

[3]

[4]